PALI-2108 is named as an intervention in 2 current clinical trials in our USA, Poland, Czechia and Canada registers. 1 is recruiting patients now. The most common phase is Phase 2. The lead sponsor is Palisade Bio. The most-studied condition is Ulcerative Colitis (UC).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07845487 · ClinicalTrials.gov ↗ · Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis
|
Phase 2 | Recruiting | Palisade Bio | USA, Poland, Czechia |
|
A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease
NCT07428096 · ClinicalTrials.gov ↗ · Fibrostenotic Crohn's Disease
|
Phase 1 | Active, closed | Palisade Bio | Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Palisade Bio | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 1 | 1 |
| Clinical trials in Poland | 1 | 1 |
| Clinical trials in Czechia | 1 | 1 |
| Clinical trials in Canada | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA, Poland, Czechia and Canada registers name PALI-2108 as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in USA, 1 with sites in Poland and 1 with sites in Czechia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Palisade Bio. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how PALI-2108 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how PALI-2108 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists PALI-2108 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.